https://www.awp.ch/sharedarticles?articleid=-1970787842
რეჯენერონი, როგორც ამერიკული ბიოტექნოლოგიური ინდუსტრიის მნიშვნელოვანი მოთამაშე, წარმატებით მართავს Eylea-ს პოსტ-პატენტურ გამოწვევებს და Dupixent-ის ექსპანსია ახალი ზრდის წყაროს ფუნქციას ასრულებს.
#drpkhakadze #sheniekimi
რეჯენერონი, როგორც ამერიკული ბიოტექნოლოგიური ინდუსტრიის მნიშვნელოვანი მოთამაშე, წარმატებით მართავს Eylea-ს პოსტ-პატენტურ გამოწვევებს და Dupixent-ის ექსპანსია ახალი ზრდის წყაროს ფუნქციას ასრულებს.
#drpkhakadze #sheniekimi
intickers.com/reports/regn/
intickers.com/reports/regn/
thebusinessresearchcompany.com/report/eylea...
thebusinessresearchcompany.com/report/eylea...
🇩🇪 #$BAYN Bayer Q3 sales €10,053m, +1.9% without currency and deals. Nubeqa €998m tops Xarelto plus Eylea. Net loss €672m after write-downs. Net debt fell on Apollo's €3.0bn.
2026 guide up: EBITDA €9.8-10.3bn, free cash flow still −€1.5 to −€0.5bn.
midgardfinance.com/companies/BAYN.DE/
🇩🇪 #$BAYN Bayer Q3 sales €10,053m, +1.9% without currency and deals. Nubeqa €998m tops Xarelto plus Eylea. Net loss €672m after write-downs. Net debt fell on Apollo's €3.0bn.
2026 guide up: EBITDA €9.8-10.3bn, free cash flow still −€1.5 to −€0.5bn.
midgardfinance.com/companies/BAYN.DE/
🇩🇪 #$BAYN Bayer Q3 sales €10,053m, +1.9% without currency and deals. Nubeqa €998m tops Xarelto plus Eylea. Net loss €672m after write-downs. Net debt fell on Apollo's €3.0bn.
2026 guide up: EBITDA €9.8-10.3bn, free cash flow still −€1.5 to −€0.5bn.
midgardfinance.com/companies/BAYN.DE/
🇩🇪 #$BAYN Bayer Q3 sales €10,053m, +1.9% without currency and deals. Nubeqa €998m tops Xarelto plus Eylea. Net loss €672m after write-downs. Net debt fell on Apollo's €3.0bn.
2026 guide up: EBITDA €9.8-10.3bn, free cash flow still −€1.5 to −€0.5bn.
midgardfinance.com/companies/BAYN.DE/
🇺🇸 #$REGN Q3 revenue $5.1bn, +36%. Regeneron's share of Dupixent and Kevzara profits, now half of revenue, rose 77% on Dupixent sales +35%, helped by repayments to Sanofi ending. Global: EYLEA HD +63%, EYLEA −49%. GAAP EPS +35%, non-GAAP +70%.
midgardfinance.com/companies/REGN/
🇺🇸 #$REGN Q3 revenue $5.1bn, +36%. Regeneron's share of Dupixent and Kevzara profits, now half of revenue, rose 77% on Dupixent sales +35%, helped by repayments to Sanofi ending. Global: EYLEA HD +63%, EYLEA −49%. GAAP EPS +35%, non-GAAP +70%.
midgardfinance.com/companies/REGN/
- Revenue $5.1B vs $4.54B est; +36% YoY
- Adj. EPS $20.07 vs $16.24 est; +70% YoY
- Dupixent global sales $6.5B (+35%), EYLEA HD $699M (+62%), Libtayo $550M (+51%) — all record quarters
- Revenue $5.1B vs $4.54B est; +36% YoY
- Adj. EPS $20.07 vs $16.24 est; +70% YoY
- Dupixent global sales $6.5B (+35%), EYLEA HD $699M (+62%), Libtayo $550M (+51%) — all record quarters
SPECTRUM is an… #ophthalmology #eye #eyenews
SPECTRUM is an… #ophthalmology #eye #eyenews
SPECTRUM is an ongoing, global, phase 4…
SPECTRUM is an ongoing, global, phase 4…
https://www.stocktitan.net/news/ALVO/alvotech-and-advanz-pharma-announce-first-known-regulatory-aj0gfaij65kh.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALVO/alvotech-and-advanz-pharma-announce-first-known-regulatory-aj0gfaij65kh.html?utm_source=stocktitan-bluesky&utm_medium=social